In the March 2019 Cannabis Business Times cover story, Dr. Andrea Small-Howard, co-founder and chief science officer of GB Sciences, said, “My personal mission is to take cannabis-based therapies to the U.S. FDA.”
More than two years later, Small-Howard, who was promoted to president of the Las-Vegas company in June, is close to her goal.
GB Sciences has completed animal studies on a treatment for Parkinson’s disease and is finalizing another animal trial of a slow-release, cannabis-based pain medication that Small-Howard calls a “game-changer” for people suffering from chronic pain. The next step is to get FDA approval on human trials, which Small-Howard hopes will be in 2022 for the Parkinson’s formulation and shortly thereafter for the pain management drug.